Literature DB >> 1694957

Epitope mapping of the HIV-1 gag region with monoclonal antibodies.

J Hinkula1, J Rosen, V A Sundqvist, T Stigbrand, B Wahren.   

Abstract

A new type of immunochemical mapping of the human immunodeficiency virus type 1 (HIV-1) gag region was performed. By use of native HIV-1 viral lysates or the gag recombinant p24-15 antigen, a new set of monoclonal antibodies (Mabs) to the gag region proteins was generated. Synthetic HIV-1 peptides covering the entire gag region were used to specifically localize the continuous epitopes by direct binding to the Mabs and by blocking the Mab immunoreactivity. The identified immunogenic epitopes were localized between the gag amino acids (aa) 108-127, 203-217, 208-222, 248-282, 273-302, 288-307, 308-322, 331-354 and 408-422. These continuous epitopes formed seven immunogenic regions. One strongly p17-reactive Mab appeared to react with a discontinuous epitope, the components of which were 110 aa distant in the linear sequence: aa 23-27 and 128-132. The synthetic peptides appeared to be more congruent with the Mab-reactive sites in solution than when coated to a solid phase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694957     DOI: 10.1016/0161-5890(90)90163-t

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  12 in total

Review 1.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

2.  Peptides isolated from random peptide libraries on phage elicit a neutralizing anti-HIV-1 response: analysis of immunological mimicry.

Authors:  K Lundin; A Samuelsson; M Jansson; J Hinkula; B Wahren; H Wigzell; M A Persson
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

3.  Vpu and Tsg101 regulate intracellular targeting of the human immunodeficiency virus type 1 core protein precursor Pr55gag.

Authors:  Kirsi Harila; Ian Prior; Mathilda Sjöberg; Antti Salminen; Jorma Hinkula; Maarit Suomalainen
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

4.  Efficiency of reinitiation of translation on human immunodeficiency virus type 1 mRNAs is determined by the length of the upstream open reading frame and by intercistronic distance.

Authors:  B G Luukkonen; W Tan; S Schwartz
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

5.  CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection.

Authors:  P J Klasse; M M Rosenkilde; N Signoret; A Pelchen-Matthews; T W Schwartz; M Marsh
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells.

Authors:  F Shang; H Huang; K Revesz; H C Chen; R Herz; A Pinter
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

7.  Comparative humoral responses to human immunodeficiency virus type 1-p24gag linear B-cell epitopes among individuals showing atypical western immunoblotting reactions and implications for diagnosis.

Authors:  J C Lallement; J P Vendrell; P Corbeau; J Ducos; M Segondy; A Escande; V Robert-Hebmann; F Jean; J Reynes; A Serre
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

8.  Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics.

Authors:  H J de Haard; B Kazemier; M J Koolen; L J Nijholt; R H Meloen; B van Gemen; H R Hoogenboom; J W Arends
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

9.  Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

Authors:  Lindvi Gudmundsdotter; Charlotta Nilsson; Andreas Brave; Bo Hejdeman; Patricia Earl; Bernard Moss; Merlin Robb; Josephine Cox; Nelson Michael; Mary Marovich; Gunnel Biberfeld; Eric Sandström; Britta Wahren
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

10.  Human MoAbs produced from normal, HIV-1-negative donors and specific for glycoprotein gp120 of the HIV-1 envelope.

Authors:  M Ohlin; J Hinkula; P A Broliden; R Grunow; C A Borrebaeck; B Wahren
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.